Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2024-512101-60-00 | EU Trial (CTIS) Number | ||
| N-A-PH1-23-067 | Other Identifier | Nuvisan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate if the trial drug vamorolone is able to block a specific receptor in the body called mineralocorticoid receptor. This receptor helps to regulate salt and water balance.
The purpose of this study is to investigate the antagonistic effect of vamorolone on the mineralocorticoid receptor following mineralocorticoid challenge by fludrocortisone, compared to eplerenone as a positive control, and to a negative control with no study treatment. Furthermore, the safety and tolerability of vamorolone combined with fludrocortisone challenge will be assessed, and the Pharmacokinetic (PK) of a single dose of vamorolone and a single dose of eplerenone, combined with fludrocortisone challenge, will be evaluated.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study arm 1 vamorolone | Experimental | Vamorolone 20 mg/kg single dose on Day 2 and Fludrocortisone challenge on Days 1 to 3 |
|
| Study arm 2 (positive control arm): eplerenone | Active Comparator | Eplerenone 200 mg single dose on Day 2 and Fludrocortisone challenge on Days 1 to 3 |
|
| Study arm 3 (negative control arm): no "active" treatment | Other | Fludrocortisone challenge on Days 1 to 3 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vamorolone | Drug | vamorolone 20 mg/kg single dose on Day 2 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Determination of the Ratio of Sodium to Potassium (Na/K) in Urine | Amounts of Na and K were calculated by multiplying the respective concentration by the volume of urine for each collection interval. The considered timepoints were: Day 1: 24-9 h and 9-0 h predose of vamorolone/eplerenone; Day 2: 0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-10 h, 10-12 h, 12-14 h, 14-16 h, 16-24 h postdose vamorolone/eplerenone or corresponding timepoint for negative control arm with fludrocortisone administrations (no treatment) Day 3: 24-32 h, 32-40 h, 40-48 h postdose vamorolone/eplerenone or corresponding timepoint for negative control arm with fludrocortisone administrations (no treatment) The individual Na/K ratio was then calculated for each urine collection interval using the amounts of Na and K. The corresponding logarithm of the Na/K ratio was determined. To avoid negative values, the ratio was multiplied by 10 before transformation, i.e., log10(10*Na/K). | Day 1, Day 2 and Day 3 |
| Measure | Description | Time Frame |
|---|---|---|
| Vamorolone PK Parameter AUC0-tlast | The area under the concentration-time curve (AUC) from time zero (= dosing time) to the time of the last quantifiable concentration (tlast). The collection points used to determine the curve were as follows: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | Day 2 |
| Vamorolone PK Parameter AUC0-inf |
Not provided
Inclusion Criteria:
Age of 18 to 55 years inclusive, at the time of signing the informed consent.
Male is overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, laboratory tests and ECG.
Body weight ≥ 50 kg and a BMI ≥ 18 kg/m2 and ≤ 29.9 kg/m2 at screening
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
If the subject is a sexually active man and not surgically sterilized, he must be willing to:
Subject is a non-smoker for at least 3 months prior to exposure to the study treatments.
Subjects must also have abstained from use of other nicotine containing products (e.g., nicotine patch, chewing gum or e-cigarettes) for at least 3 months before exposure to the study treatment.
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and in this protocol prior to any clinical study specific procedure.
Supine systolic blood pressure of ≥ 90 mmHg and ≤ 140 mmHg, diastolic blood pressure of ≥ 50 mmHg and ≤ 90 mmHg, pulse rate of ≥ 45 bpm and ≤ 90 bpm, and tympanic body temperature of ≥ 35.0 and ≤ 37.5°C at screening.
Subjects must be able to communicate well with the Investigator and comply with the protocol requirements, instructions, and protocol related restrictions (e.g., dietary, fluid and lifestyle restrictions from screening to study completion)
Subjects must be able to swallow the study treatments as per protocol
Exclusion Criteria:
A past medical history of clinically significant abnormalities or a history/family history of long QT interval syndrome.
An abnormal ECG, defined as:
A past medical history of myocardial infarction, angina pectoris, atherosclerosis, or other clinically significant heart disease (e.g.congestive heart failure, uncontrolled hypertension, history of labile hypertension)
A past medical history of peptic ulcers, diverticulitis, and non-specific ulcerative colitis.
History of complaints of frequent dizziness and /or vomiting spells or lightheadedness.
Any history or evidence of any clinically relevant, gastrointestinal, respiratory, hepatic, renal, endocrinologic, hematologic, immunologic, metabolic, genitourinary, pulmonary, neurologic, dermatologic, musculoskeletal, and/or other major disease or malignancy as determined by medical evaluation (including physical examination) capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatments; or interfering with the interpretation of data.
Known Gilbert's syndrome.
Any clinically relevant history of allergic conditions requiring hospitalization or prolonged systemic treatment (including drug allergies, allergic asthma, eczema, allergies requiring therapy with corticosteroids or anaphylactic reactions); but excluding untreated, asymptomatic, seasonal allergies at time of dosing or allergic contact sensitizations (e.g., nickel allergy).
Known or suspected hypersensitivity or contraindications to the study treatments or any components of the formulation used, e.g., vamorolone, eplerenone and fludrocortisone.
Relevant current acute or chronic/recurrent viral, bacterial, fungal or parasitic infections (e.g., pulmonary/upper respiratory, gastrointestinal, urinary, skin, or ear, nose and throat (ENT) infections) at screening or within 28 days prior to administration of the study treatments.
Use of any concomitant medication or any drugs / medicines (including dietary supplements, natural and herbal remedies, and hormone replacement therapy) within 2 weeks or 5 times the half-life of the respective drug, whichever is longer, prior to the first administration of the study treatments.
Occasional use of paracetamol up to 2 g/day (medicinal product in its original packaging, approved and marketed in Germany) is permitted.
Oral, injectable, and implantable contraceptives as outlined in protocol section 5.1 are permitted.
Previous exposure to vamorolone.
Any use of corticoids within 6 months prior to the first administration of the study treatments.
Administration of live, attenuated, replication-competent vaccines within 6 weeks prior to the first administration of study treatment until 2 weeks after the follow-up visit. Administration of inactivated vaccines or vector-based or messenger ribonucleic acid (mRNA ) COVID-19 vaccines within 2 weeks prior to the first administration of the study treatments until 2 weeks after the follow-up visit.
Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the first administration of the study treatments.
Use of any investigational drug or participation in any clinical study within 30 days or 5 half-lives (whichever is longer) prior to the expected date of first administration of study treatments or planning to take other investigational drugs during the study.
Positive results for HBsAg, anti-HCV (Hepatitis C virus), anti-HIV 1 and 2, and HIV 1-p24 antigen at screening.
Positive screen for alcohol, drugs of abuse and cotinine at screening.
Elevations in Alanine aminotransferase (ALT) ≥ 1.1 x ULN (Upper limit of normal) , AST (Aspartate aminotransferase) ≥ 1.1 x ULN, serum bilirubin ≥ 1.0 x ULN, creatinine ≥1.0 x ULN and HbA1c > ULN at screening. A case-by-case decision for any abnormality must be discussed with the Sponsor before inclusion.
Sodium, potassium, magnesium, chloride blood concentration below the lower limit of normal at screening.
Thyroid-stimulating hormone (TSH) and coagulation outside of normal ranges.
eGFR (Estimated glomerular filtration rate) based on the Chronic kidney disease epidemiology collaboration (CKD-EPI) of < 90 mL/min at screening.
Subjects who are unwilling to adhere to contraceptive requirements.
Higher than low-risk alcohol consumption i.e., consumption of an average weekly alcohol intake of > 21 units/week for men. 1 unit (12 g) corresponds to 0.3 L of beer/day or 0.12 L of wine/day or 1 glass (at 2 cL) of spirits/day.
Excessive consumption of caffeine- or xanthine-containing food or beverages (> 5 cups of coffee a day or equivalent) or inability to stop consuming from 48 hours prior to first planned administration of study treatments.
Consumption of alcohol from 48 hours prior to admission
Consumption of high-dose resveratrol-containing products or products with enzyme-inducing or enzyme-inhibiting properties 14 days prior to first administration of study treatments.
Regular consumption of poppy seed containing food prior to first administration of study treatments.
No sweets/teas containing liquorice are allowed within 2 weeks prior to first administration of study treatments up to the follow-up examination.
Any use of drugs-of-abuse or alcohol abuse within 1 month prior to dosing.
Subject with vegetarian, vegan, or restricted diet (e.g., gluten-free) or not willing or able to eat the complete standard meals.
Donation or loss of more than 400 mL of blood or received a transfusion of any blood or blood products within 30 days, or donated plasma within 30 days prior to first administration of study treatments.
Strenuous physical activity within 72 h to admission.
Employee of the Sponsor, the Nuvisan Group, or other Contract Research Organization involved in the clinical study.
Legal incapacity or limited legal capacity, or incarceration and vulnerable subjects.
Inability to understand or communicate reliably with the Investigator or considered by the Investigator to be unable to or unlikely to co-operate with the protocol requirements, instructions, and study-related restrictions
History of non-compliance to medical regimens and subjects who are considered potentially unreliable (e.g., refuse to comply with study regulations).
Any other conditions or factors which in the opinion of the Investigator may interfere with study conduct.
Changes in medical conditions compared to screening, as judged by the Investigator.
Body weight < 50 kg.
Changes in prior/concomitant therapy compared to screening, as judged by the Investigator.
Positive for an acute common cold/respiratory or other infection upon admission.
Positive screen for alcohol, drugs of abuse and cotinine test upon admission.
Changes in other exclusion criteria compared to screening, as judged by the Investigator.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Steffen Haffner, MD | Nuvisan GmbH | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nuvisan GmbH | Neu-Ulm | 89231 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40957504 | Derived | de Vera A, Clemens PR, Dang UJ, Dutreix C, Gresko E, Guglieri M, Hagerty L, Hasham S, Damsker J, Hathout Y, Linden A, Berglund A, Tobin R, Wahbi K, Hoffman EP. Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials. Steroids. 2025 Nov;223:109689. doi: 10.1016/j.steroids.2025.109689. Epub 2025 Sep 14. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Study Arm 1 (Test Arm)Vamorolone | single oral dose of vamorolone 20 mg/kg on day 2 + Fludrocortisone Challenge Day 1: 1 mg single dose at 9 h predose vamorolone dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose vamorolone dosing. Vamorolone: vamorolone 20 mg/kg single dose on Day 2 Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
| FG001 | Study Arm 2 (Positive Control Arm): Eplerenone | single oral dose of eplerenone 200 mg on day 2 + Fludrocortisone challenge Day 1: 1 mg single dose at 9 h predose eplerenone dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose eplerenone dosing. Eplerenone: Eplerenone 200 mg single dose on Day 2 Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
| FG002 | Study Arm 3 (Negative Control Arm): no Treatment | Fludrocortisone challenge only Day 1: 1 mg single dose at 9 h predose vamorolone/eplerenone* dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose vamorolone/eplerenone* dosing. *or corresponding timepoint for negative control arm Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Safety Set: All subjects assigned (randomized) to study treatment and received at least 1 dose of study treatment. Subjects were analyzed according to the treatment they received.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Study Arm 1 (Test Arm)Vamorolone | single oral dose of vamorolone 20 mg/kg on day 2 + Fludrocortisone Challenge Day 1: 1 mg single dose at 9 h predose vamorolone dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose vamorolone dosing. Vamorolone: vamorolone 20 mg/kg single dose on Day 2 Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Determination of the Ratio of Sodium to Potassium (Na/K) in Urine | Amounts of Na and K were calculated by multiplying the respective concentration by the volume of urine for each collection interval. The considered timepoints were: Day 1: 24-9 h and 9-0 h predose of vamorolone/eplerenone; Day 2: 0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-10 h, 10-12 h, 12-14 h, 14-16 h, 16-24 h postdose vamorolone/eplerenone or corresponding timepoint for negative control arm with fludrocortisone administrations (no treatment) Day 3: 24-32 h, 32-40 h, 40-48 h postdose vamorolone/eplerenone or corresponding timepoint for negative control arm with fludrocortisone administrations (no treatment) The individual Na/K ratio was then calculated for each urine collection interval using the amounts of Na and K. The corresponding logarithm of the Na/K ratio was determined. To avoid negative values, the ratio was multiplied by 10 before transformation, i.e., log10(10*Na/K). | This set is a subset of the Safety Set and includes all subjects who completed the study without any findings/events likely affecting Pharmacodynamic (PD). | Posted | Geometric Mean | Standard Deviation | log10(10*Na/K) | Day 1, Day 2 and Day 3 |
All adverse events AEs)and serious AE(SAEs) were collected from the signing of the informed consent until the safety follow-up phone call on Day11. All SAEs were to be recorded & reported to the sponsor within 24hours of awareness,filing in the safety form provided. Investigators were not obligated to actively seek AEs or SAEs after conclusion of the study participation. If the investigator learned of any SADR (SAE considered related to the IMP) at any time it had to be reported to the sponsor
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Study Arm 1 (Test Arm)Vamorolone | single oral dose of vamorolone 20 mg/kg on day 2 + Fludrocortisone Challenge Day 1: 1 mg single dose at 9 h predose vamorolone dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose vamorolone dosing. Vamorolone: vamorolone 20 mg/kg single dose on Day 2 Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | Nervous system disorders | MedDRA (27.0) | Systematic Assessment | Mild headache was reported approximately 1 hour after vamorolone administration on Day 2 and lasted for 7.5 h. The event resolved without any concomitant medication but was condisered related to vamolorone. |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Shabir Hasham MD, Chief Medical Officer | Santhera Pharmaceuticals LTD | +41 79 520 95 18 | shabir.hasham@santhera.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 26, 2024 | Jul 28, 2025 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jul 17, 2024 | Jul 28, 2025 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| C584811 | VBP15 compound |
| D015507 | Drugs, Investigational |
| D000077545 | Eplerenone |
| D005438 | Fludrocortisone |
| ID | Term |
|---|---|
| D004364 | Pharmaceutical Preparations |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D011283 | Pregnenes |
Not provided
Not provided
This study will be conducted in a single-center, randomized, open-label, 3-arm, parallel-group, positive- and negative-controlled design.
Not provided
Not provided
Not provided
Not provided
| Eplerenone | Drug | Eplerenone 200 mg single dose on Day 2 |
|
|
| Fludrocortisone | Drug | Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
|
|
The AUC from time zero (dosing time) extrapolated to infinity estimated. The collection points used to determine the curve were as follows: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 |
| Day 2 |
| Vamorolone PK Parameter Cmax | Maximum plasma drug concentration after administration of vamorolone. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | Day 2 |
| Vamorolone PK Parameter Tmax | Time to reach maximum concentration following vamorolone administration. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | Day 2 |
| Vamorolone PK Parameter t1/2 | Elimination half-life is the amount of time it takes for the concentration of a drug in the body to decrease by half. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | Day 2 |
| Eplerenone PK Parameters AUC0-tlast | The area under the concentration-time curve (AUC) from time zero (= dosing time) to the time of the last quantifiable concentration (tlast).The collection points used to determine the curve were as follows: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | Day 2 |
| Eplerenone PK Parameter AUC0-inf | The AUC from time zero (dosing time) extrapolated to infinity. The collection points used to determine the curve were as follows: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | Day 2 |
| Eplerenone PK Parameter Cmax | Maximum plasma drug concentration after administration of eplerenone. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | Day 2 |
| Eplerenone PK Parameter Tmax | Time to reach to the maximum concentration after eplerenone. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | Day 2 |
| Eplerenone PK Parameter t1/2 | Elimination half-life is the amount of time it takes for the concentration of a drug in the body to decrease by half. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | Day 2 |
| BG001 | Study Arm 2 (Positive Control Arm): Eplerenone | single oral dose of eplerenone 200 mg on day 2 + Fludrocortisone challenge Day 1: 1 mg single dose at 9 h predose eplerenone dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose eplerenone dosing. Eplerenone: Eplerenone 200 mg single dose on Day 2 Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
| BG002 | Study Arm 3 (Negative Control Arm): no Treatment | Fludrocortisone challenge only Day 1: 1 mg single dose at 9 h predose vamorolone/eplerenone* dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose vamorolone/eplerenone* dosing. *or corresponding timepoint for negative control arm Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| BMI | Mean | Standard Deviation | kg/m2 |
|
| Weight | Mean | Standard Deviation | kg |
|
| Height | Mean | Standard Deviation | cm |
|
| ID |
|---|
| Title |
|---|
| Description |
|---|
| OG000 | Study Arm 1 (Test Arm)Vamorolone | single oral dose of vamorolone 20 mg/kg on day 2 + Fludrocortisone Challenge Day 1: 1 mg single dose at 9 h predose vamorolone dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose vamorolone dosing. Vamorolone: vamorolone 20 mg/kg single dose on Day 2 Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
| OG001 | Study Arm 2 (Positive Control Arm): Eplerenone | single oral dose of eplerenone 200 mg on day 2 + Fludrocortisone challenge Day 1: 1 mg single dose at 9 h predose eplerenone dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose eplerenone dosing. Eplerenone: Eplerenone 200 mg single dose on Day 2 Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
| OG002 | Study Arm 3 (Negative Control Arm): no Treatment | Fludrocortisone challenge only Day 1: 1 mg single dose at 9 h predose vamorolone/eplerenone* dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose vamorolone/eplerenone* dosing. *or corresponding timepoint for negative control arm Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. |
|
|
| Secondary | Vamorolone PK Parameter AUC0-tlast | The area under the concentration-time curve (AUC) from time zero (= dosing time) to the time of the last quantifiable concentration (tlast). The collection points used to determine the curve were as follows: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | This set is a subset of the Safety Set and includes all subjects who completed the study without any findings/events likely affecting PK. | Posted | Mean | Standard Deviation | h*ng/ml | Day 2 |
|
|
|
| Secondary | Vamorolone PK Parameter AUC0-inf | The AUC from time zero (dosing time) extrapolated to infinity estimated. The collection points used to determine the curve were as follows: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | This set is a subset of the Safety Set and includes all subjects who completed the study without any findings/events likely affecting PK. | Posted | Mean | Standard Deviation | h*ng/ml | Day 2 |
|
|
|
| Secondary | Vamorolone PK Parameter Cmax | Maximum plasma drug concentration after administration of vamorolone. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | This set is a subset of the Safety Set and includes all subjects who completed the study without any findings/events likely affecting PK. | Posted | Mean | Standard Deviation | ng/mL | Day 2 |
|
|
|
| Secondary | Vamorolone PK Parameter Tmax | Time to reach maximum concentration following vamorolone administration. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | This set is a subset of the Safety Set and includes all subjects who completed the study without any findings/events likely affecting PK. | Posted | Median | Full Range | h | Day 2 |
|
|
|
| Secondary | Vamorolone PK Parameter t1/2 | Elimination half-life is the amount of time it takes for the concentration of a drug in the body to decrease by half. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | This set is a subset of the Safety Set and includes all subjects who completed the study without any findings/events likely affecting PK. | Posted | Mean | Standard Deviation | h | Day 2 |
|
|
|
| Secondary | Eplerenone PK Parameters AUC0-tlast | The area under the concentration-time curve (AUC) from time zero (= dosing time) to the time of the last quantifiable concentration (tlast).The collection points used to determine the curve were as follows: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | This set is a subset of the Safety Set and includes all subjects who completed the study without any findings/events likely affecting PK. | Posted | Mean | Standard Deviation | h*ng/ml | Day 2 |
|
|
|
| Secondary | Eplerenone PK Parameter AUC0-inf | The AUC from time zero (dosing time) extrapolated to infinity. The collection points used to determine the curve were as follows: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | This set is a subset of the Safety Set and includes all subjects who completed the study without any findings/events likely affecting PK. | Posted | Mean | Standard Deviation | h*ng/ml | Day 2 |
|
|
|
| Secondary | Eplerenone PK Parameter Cmax | Maximum plasma drug concentration after administration of eplerenone. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | This set is a subset of the Safety Set and includes all subjects who completed the study without any findings/events likely affecting PK. | Posted | Mean | Standard Deviation | ng/ml | Day 2 |
|
|
|
| Secondary | Eplerenone PK Parameter Tmax | Time to reach to the maximum concentration after eplerenone. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | Posted | Median | Full Range | h | Day 2 |
|
|
|
| Secondary | Eplerenone PK Parameter t1/2 | Elimination half-life is the amount of time it takes for the concentration of a drug in the body to decrease by half. For this PK measure, the following timepoints were considered: predose; and 1, 2, 4, 8, 12, 24 h postdose on Day 2 | This set is a subset of the Safety Set and includes all subjects who completed the study without any findings/events likely affecting PK. | Posted | Mean | Standard Deviation | h | Day 2 |
|
|
|
| 0 |
| 10 |
| 0 |
| 10 |
| 1 |
| 10 |
| EG001 | Study Arm 2 (Positive Control Arm): Eplerenone | single oral dose of eplerenone 200 mg on day 2 + Fludrocortisone challenge Day 1: 1 mg single dose at 9 h predose eplerenone dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose eplerenone dosing. Eplerenone: Eplerenone 200 mg single dose on Day 2 Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. | 0 | 10 | 0 | 10 | 2 | 10 |
| EG002 | Study Arm 3 (Negative Control Arm): no Treatment | Fludrocortisone challenge only Day 1: 1 mg single dose at 9 h predose vamorolone/eplerenone* dosing. Day 2: 0.1 mg and 0.5 mg multiple doses. For detailed timepoints, see protocol Section 4.1. Day 3: 0.1 mg single dose at 24 h postdose vamorolone/eplerenone* dosing. *or corresponding timepoint for negative control arm Fludrocortisone: Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2:
Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm. | 0 | 10 | 0 | 10 | 0 | 10 |
|
| Nasopharyngitis | Infections and infestations | MedDRA (27.0) | Systematic Assessment | Two mild nasopharyngitis in subjects treated with eplerenone. One with rhinitis and pharyngitis started on Day 7 and resolved in about 4 days. The other started on Day 5 and took about 8 days to resolve. Neither subject took concomitant medication. |
|
| Circulatory collaspse | Vascular disorders | MedDRA (27.0) | Systematic Assessment | A subject treated with eplerenone experienced moderate circulatory collapse on Day 4, which lasted approximately one hour. This event was not considered to be related to the study treatment. |
|
Not provided
Not provided
| D011278 |
| Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D006854 | Hydrocortisone |
| D011282 | Pregnenediones |